Physician profile
Daniel B Williams
NPI 1629093638
$4,876.62
in general payments reported to CMS, 2019-2025
41 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $82.44 · 2021: $25.97 · 2022: $445 · 2023: $1,013 · 2024: $1,323 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,193.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,321.86 | 2022-2025 | Vraylar, Rinvoq, Dalvance |
| Glaxosmithkline, LLC. | $558.69 | 2021-2025 | Benlysta, Trelegy Ellipta, Arexvy |
| Janssen Biotech, INC. | $348.76 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $324.54 | 2022-2025 | Saphnelo, Airsupra, Breztri |
| Amgen INC. | $282.68 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Ucb, INC. | $180.97 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $151.02 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $148.64 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.79 | 2023-2025 | |
| Indivior INC. | $131.44 | 2022-2025 | Sublocade |
| Ani Pharmaceuticals, INC. | $120.54 | 2024-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $120.07 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Antares Pharma, INC. | $114.48 | 2024-2025 | Xyosted |
| Paratek Pharmaceuticals, INC. | $68.52 | 2024 | Nuzyra |
| Tolmar, INC. | $67.36 | 2024-2025 | Jatenzo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.